Let's consider one company in each category. The one that could benefit from Anthropic's IPO is Broadcom ( AVGO -5.48%), and ...
With a one-of-a-kind platform that can run and analyze millions of experiments at a time, Recursion could change the drug-discovery process. The stock market, though, isn't that impressed, and the ...
Monday - Friday, 6:00 - 7:00 PM ET In a Friday interview with CNBC's Jim Cramer, Recursion Pharmaceuticals CEO Chris Gibson discussed how his company is using artificial intelligence and machine ...
When studying programming, you notice something strange.Processes that are extremely complex for humans to think through can sometimes be written surprisingly concisely using functions.A prime example ...
Recursion Pharmaceuticals has had a rough ride on the market lately, and the slide raises a simple question for investors who ...
SALT LAKE CITY, Nov. 8, 2018 /PRNewswire/ -- Recursion Pharmaceuticals, a biotechnology company that combines artificial intelligence (AI), experimental biology, and automation to discover and develop ...
Chris Gibson, Recursion Pharmaceuticals CEO, joins 'Closing Bell Overtime' to talk its partnership with Nvidia, its investors day, drug discovery and more. Got a confidential news tip? We want to hear ...
Tech Times on MSN
Recursive launches Flint AI, free coding model that runs on laptops
Read about Recursive's Flint AI coding model, its laptop-friendly design, coding benchmarks, open-source license, and Eureka ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results